NASDAQ:PLTX

Peloton Therapeutics, Inc., a clinical stage biopharmaceutical company, develops medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is PT2977, an oral HIF-2a inhibitor that is in Phase 2 clinical trials for use in patients with advanced or metastatic clear cell renal cell carcinoma (mRCC). The company is also evaluating PT2977 in Phase 2 clinical trials in von Hippel-Lindau disease associated renal cell carcinoma; Phase 2 clinical trials in combination with cabozantinib, a vascular endothelial growth factor receptor-targeting agent in mRCC; Phase 1/2 dose-escalation and dose-expansion clinical trials in patients with mRCC; and Phase 1/2 clinical trial in glioblastoma multiforme. In addition, it is developing PT2567, an oral HIF-2a inhibitor in preclinical development for non-oncology indications, including pulmonary arterial hypertension. The company was formerly known as Damascus Pharmaceutics, Inc. and changed its name to Peloton Therapeutics, Inc. in June 2011. Peloton Therapeutics, Inc. was founded in 2010 and is headquartered in Dallas, Texas. As of July 30, 2019, Peloton Therapeutics, Inc. operates as a subsidiary of Merck & Co., Inc.